X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The proceeds from the financing will enable Epsilogen to establish clinical proof of concept for lead drug candidate MOv18 IgE in a phase Ib trial in platinum-resistant ovarian cancer, an aggressive cancer with poor treatment alternatives.
Lead Product(s): MOv18 IgE
Therapeutic Area: Oncology Product Name: MOv18 IgE
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Novartis Venture Fund
Deal Size: $41.2 million Upfront Cash: Undisclosed
Deal Type: Series B Financing March 02, 2022
Details:
Epsilogen will collaborate with King’s College London (KCL) and use the funding from the grant to further develop the company’s novel cancer immunotherapeutic EPS 201.
Lead Product(s): EPS 201
Therapeutic Area: Oncology Product Name: EPS 201
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Innovate UK
Deal Size: $1.3 million Upfront Cash: Undisclosed
Deal Type: Funding October 21, 2020
Details:
MOv18 IgE, at the doses administered, was found to be well tolerated in almost all patients, with urticaria1 being the most frequently observed adverse event.
Lead Product(s): MOv18 IgE
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2020
Details:
The antibody developed at KCL in collaboration with Cancer Research UK is the first therapeutic IgE antibody to enter clinical trials.
Lead Product(s): MOv18 IgE
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Kings College London
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 21, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
